We consider a modern treatment algorithm for type 2 diabetes mellitus (DM2), and provide advisability of insulinotherapy on specific stages of the disease. It is emphasized that approximately 80% of patients with DM2 requires permanent insulinotherapy at 10-12 years after diagnosis. We present data from clinical studies dedicated to use of insulin analogues glargine (Lansus) and glulisine (Apidra) in basal-bolus regimen in patients with DM2 in case of ineffectiveness of peroral antihyperglycemic therapy. Available experience of insulin Lantus and Apidra use in DM2 demonstrates high efficacy and safety of this treatment regimen in terms of achieving good glicemic control and improvement of quality of life, as well as economic viability.

Keywords: basal-bolus regimen, glulisine, glargine, insulinotherapy, type 2 diabetes mellitus